ResMed Chief Administrative Officer and Global General Counsel to Retire
March 30 2023 - 4:05PM
ResMed Chief Administrative Officer and Global General Counsel to
Retire
ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis,
chief administrative officer, global general counsel, and
secretary, plans to retire, effective June 30, 2023. He will remain
in a consulting role with ResMed through December 31, 2023.
ResMed will conduct an internal search for the successor to
Pendarvis’ legal roles and expects to name a new global general
counsel and secretary well ahead of David’s retirement date to
ensure a smooth and seamless transition. Amy Wakeham, ResMed’s
current Vice President of Corporate Communications & Investor
Relations, has been appointed Chief Communications and Investor
Relations Officer to succeed Pendarvis in his role leading
corporate public affairs; she will report to the Office of the CEO
and will join ResMed’s executive leadership team, effective April
1, 2023.
“Dave has been an integral part of ResMed for over 20 years,
helping guide the company into and through its transformation from
the pioneer of sleep apnea treatment to a $30 billion-plus global
leader in digital health and cloud-connected medical devices,” said
CEO Mick Farrell. “On behalf of the entire management team and the
board, I want to thank Dave for his two decades of dedicated
service and exemplary leadership that has helped build the
industry-leading company that ResMed is today. He’s been an
important leader in an executive team that has positioned ResMed to
improve the lives of many millions of people living with chronic
respiratory diseases and countless more seeking to age healthily
and outside the hospital. Personally, Dave has been a trusted
advisor, partner, friend, and mentor to me through the years, I
will miss his guidance, insights, and quick sense of humor.”
“My best wishes to Dave on a much-deserved retirement, and
congratulations to Amy on her well-earned appointment,” Farrell
said. “Through an internal search process, we will identify a
well-qualified successor for the global general counsel role ahead
of Dave’s retirement to ensure a smooth transition into these
critical roles. This speaks to the overall depth of ResMed’s
leadership bench strength and broad expertise across our global
team of over 10,000 ResMedians as we continue to execute our
strategy that will help 250 million people sleep, breathe, and live
healthier lives in 2025.”
Pendarvis, age 64, retires after a nearly 40-year career in law
and business. He joined ResMed in 2002, following private practice
as a partner with the firms of Gibson Dunn and Gray Cary Ware &
Freidenrich (now DLA Piper). He has had several roles at ResMed:
global general counsel, secretary, senior vice president of
organizational development, chief administrative officer, and
interim president – Europe, Middle East, Africa, and Japan.
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies” and cloud-connected medical
devices transform care for people with sleep apnea, COPD, and other
chronic diseases. Our comprehensive out-of-hospital software
platforms support the professionals and caregivers who help people
stay healthy in the home or care setting of their choice. By
enabling better care, we improve quality of life, reduce the impact
of chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more, visit
ResMed.com and follow @ResMed.
For
media |
For
investors |
news@resmed.com |
investorrelations@resmed.com |
+1 858.836.6798 |
+1 858.836.5000 |
Resmed (LSE:0KW4)
Historical Stock Chart
From Nov 2024 to Dec 2024
Resmed (LSE:0KW4)
Historical Stock Chart
From Dec 2023 to Dec 2024